AFQ056 for Language Learning in Children With FXS

NCT02920892 ↗

Phase 2 Completed 110 enrolled Elizabeth Berry-Kravis National Institute of Neurological Disorders and Stroke (NINDS) · collab Novartis Pharmaceuticals · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical trial is to investigate the impact of AFQ056 on language learning in 3-6 year old children with Fragile X Syndrome (FXS).

Timeline

Start: 2017-08-17
Primary completion: 2022-05-17
Completion: 2022-05-17

Publications

Protic D, Breeze E, Mendoza G, Zafarullah M, Abbeduto L, Hagerman R, Coffey C, Cudkowicz M, Durbin-Johnson B, Ashwood P, Berry-Kravis E, Erickson CA, Filipink R, Gropman A, Lehwald L, Maxwell-Horn A, Morris S, Bennett AP, Prock L, Talboy A, Tartaglia N, Veenstra-VanderWeele J, Tassone F. Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome. SAGE Open Med. 2024 Sep 29;12:20503121241282401. doi: 10.1177/20503121241282401. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mavoglurant	Small molecule	12.5 mg	Oral
Subject	Mavoglurant	Small molecule	100 mg	Oral

AFQ056 for Language Learning in Children With FXS

Summary

Timeline

Publications

Drugs

Indications